Knyazev

Dmitriy Knyazev, Windsor CA

Patent application number	Description	Published
20100298992	System for Controlling the Heating and Housing Units in a Building - The present invention is a system for controlling the heating of a plurality of individual housing units in a building. The system includes at least one heating unit contained in each individual housing unit for heating said individual housing unit and a control unit coupled to each of the heating units for controlling the heat output of the control units. At least one outside temperature sensor is coupled to the control unit for providing the control unit with the measured temperature of the air outside the building. The control unit has an algorithm which is configured to decrease the heat output of the heating units when the temperature of the air outside the building increases beyond a predefined minimum outside temperature.	11-25-2010

Patent application number	Description	Published
20110033482	HER3 AS A DETERMINANT FOR THE PROGNOSIS OF MELANOMA - Disclosed are inhibitors of HER3 for the treatment of melanoma, in particular melanoma metastases and/or refractory melanoma, pharmaceutical compositions comprising such an inhibitor and a method for the diagnosis or prognosis of melanoma.	02-10-2011
20110092503	QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS - Novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family are described herein. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.	04-21-2011

Patent application number	Description	Published
20100184686	USE OF INHIBITORS FOR THE TREATMENT OF RTK-HYPERFUNCTION-INDUCED DISORDERS, PARTICULARLY CANCER - The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to over-expression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule. Finally, in addition the invention concerns a pharmaceutical composition, containing the inhibitor as described above and further a diagnostic and screening procedure.	07-22-2010